The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization
Abstract
Interphase fluorescence in situ hybridization (FISH) studies of chromosomal region 13q14 were performed to investigate the incidence and clinical importance of deletions in multiple myeloma (MM). Monoallelic deletions of the retinoblastoma-1 (rb-1) gene and the D13S319 locus were observed in 48 of 104 patients (46.2%) and in 28 of 72 (38.9%) patients, respectively, with newly diagnosed MM. FISH studies found that 13q14 was deleted in all 17 patients with karyotypic evidence of monosomy 13 or deletion of 13q but also in 9 of 19 patients with apparently normal karyotypes. Patients with a 13q14 deletion were more likely to have stage III disease (P = .022), higher serum levels of β2-microglobulin (P = .059), and a higher percentage of bone marrow plasma cells (P = .085) than patients with a normal 13q14 status on FISH analysis. In patients with a deletion of 13q14, myeloma cell proliferation (Ki-67) was markedly increased (22.0% ± 6.9% compared with 15.6% ± 8.2% in patients without the deletion;P = .0008). Evaluation of bromodeoxyuridine incorporation in 5 patients revealed that both rb-1–deleted and rb-1–normal MM subpopulations were proliferative. The presence of a 13q14 deletion on FISH analysis was associated with a significantly lower rate of response to conventional-dose chemotherapy (40.8% compared with 78.6%; P = .009) and a shorter overall survival (24.2 months compared with > 60 months; P < .005) than in patients without the deletion. Multivariate analysis of prognostic factors confirmed the independent predictive value of 13q14 deletions for shortened survival. In conclusion, deletions of 13q14 are frequently detected by interphase FISH in patients with newly diagnosed MM, correlate with increased proliferative activity, and represent an independent adverse prognostic feature in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995) · Blood · doi:10.1182/blood.v86.11.4250.bloodjournal86114250 · Cited by 395
Santhanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Nilsson, K., Bennich, H., Johansson, S. G. O., & Pontén, J. (1970) · PubMed Central · Cited by 368
Drach, J., Ackermann, J., Fritz, E., Krömer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., et al. (1998) · Blood · doi:10.1182/blood.v92.3.802 · Cited by 325
Self-citationGreipp, P., Lust, J., O'Fallon, W., Katzmann, J., Witzig, T., & Kyle, R. (1993) · Blood · doi:10.1182/blood.v81.12.3382.3382 · Cited by 312
Bartl, R., Frisch, B., Fateh-Moghadam, A., Kettner, G., Jaeger, K., & Sommerfeld, W. (1987) · American Journal of Clinical Pathology · doi:10.1093/ajcp/87.3.342 · Cited by 288
Drach, J., Gsur, A., Hamilton, G., Zhao, S., Angerler, J., Fiegl, M., Zojer, N., Raderer, M., Haberl, I., Andreeff, M., et al. (1996) · Blood · doi:10.1182/blood.v88.5.1747.1747 · Cited by 224
Self-citationLai, J., Zandecki, M., Mary, J., Bernardi, F., Izydorczyk, V, Flactif, M., Morel, P., Jouet, J., Bauters, F., & Facon, T. (1995) · Blood · doi:10.1182/blood.v85.9.2490.bloodjournal8592490 · Cited by 216
Avet-Loiseau, H., Li, J.-Y., Morineau, N., Facon, T., Brigaudeau, C., Harousseau, J.-L., Grosbois, B., & Bataille, R. (1999) · Blood · doi:10.1182/blood.v94.8.2583.420a05_2583_2589 · Cited by 192
Drach, J. W., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C. A., Gsur, A., Jaeger, U., & Heinz, R. (1995) · PubMed · Cited by 192
Self-citationTricot, G., Sawyer, J. R., Jagannath, S., Desikan, K. R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N., & Barlogie, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2659 · Cited by 172
Pérez-Simón, J. A., Garcı́a-Sanz, R., Tabernero, M. D., Almeida, J., González, M., Fernández-Calvo, J., Moro, M. J., Hernández, J. M., Miguel, J. F. S., & Orfão, A. (1998) · Blood · doi:10.1182/blood.v91.9.3366 · Cited by 169
MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL
Zandecki, M., Laï, J. L., & Facon, T. T. F. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-2939.x · Cited by 148
Cigudosa, J. C., Rao, P. H., Calasanz, M. J., et al. (1998) · Blood · doi:10.1182/blood.v91.8.3007.3007_3007_3010 · Cited by 146
Prognostic value of cytogenetics in multiple myeloma
Seong, C., Delasalle, K. B., Hayes, K. J., Weber, D., Dimopoulos, M. A., Swantkowski, J., Huh, Y. O., Glassman, A. B., Champlin, R. E., & Alexanian, R. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00657.x · Cited by 145
A new staging system for multiple myeloma based on the number of S- phase plasma cells
Miguel, J. F. S., García‐Sánz, R., González, M., et al. (1995) · Blood · doi:10.1182/blood.v85.2.448.bloodjournal852448 · Cited by 135
13q deletions in lymphoid malignancies
Liu, Y., Hermanson, M., Grandér, D., Merup, M., Wu, X., Heyman, M. M., Rasool, O., Juliusson, G., Gahrton, G., & Detlofsson, R. (1995) · Blood · doi:10.1182/blood.v86.5.1911.bloodjournal8651911 · Cited by 130
Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
Urashima, M., Ogata, A., Chauhan, D., Vídriales, M., Teoh, G., Hoshi, Y., Schlossman, R., DeCaprio, J. A., & Anderson, K. C. (1996) · Blood · doi:10.1182/blood.v88.6.2219.bloodjournal8862219 · Cited by 107
Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia
Bullrich, F., Veronese, M. L., Kitada, S., Jurlander, J., Caligiuri, M. A., Jc, R., & Croce, C. M. (1996) · Blood · doi:10.1182/blood.v88.8.3109.bloodjournal8883109 · Cited by 102
Avet‐Loiseau, H., Andree-Ashley, L. E., Moore, D. H., Mellerin, M., Feusner, J. D., Bataille, R., & Pallavicini, M. G. (1997) · Genes Chromosomes and Cancer · Cited by 97
Histologic classification and staging of multiple myeloma
Bartl, R. (1988) · Hematological Oncology · doi:10.1002/hon.2900060209 · Cited by 92
Deletion of the retinoblastoma gene in multiple myeloma.
Dao, D., Sawyer, J. R., Epstein, J., Hoover, R. G., Barlogie, B., & Tricot, G. J. K. (1994) · PubMed · Cited by 84
Karyotype in multiple myeloma and plasma cell leukaemia
Weh, H. J., Gutensohn, K., Selbach, J., Kruse, R., Wacker-Backhaus, G., Seeger, D. R., Fiedler, W., Fett, W., & HOSSFELD, D. K. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90071-m · Cited by 84
FLACTIF, M., Zandecki, M., Laï, J. L., et al. (1995) · PubMed · Cited by 83
Chang, H., Bouman, D., Boerkoel, C. F., Stewart, A. K., & Squire, J. A. (1999) · Leukemia · doi:10.1038/sj.leu.2401208 · Cited by 39
Among numerous DNA copy number changes, losses of chromosome 13 are highly recurrent in plasmacytoma
Aalto, Y., Nordling, S., Kivioja, A., Karaharju, E. O., Elomaa, I., & Knuutila, S. (1999) · Genes Chromosomes and Cancer · Cited by 32
Cited by
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Genetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 687
Self-citation
Metadata
- Authors
- Zojer, N., Königsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Krömer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., Heinz, R., Ludwig, H., Huber, H., & Drach, J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-03-15
- Volume
- 95
- Issue
- 6
- Pages
- 1925-1930
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1538098067
- Cited by
- 321
- References
- 28
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.